Based on our findings, we asked whether the FLT3 inhibitors, which are developed for AML patients, could be repurposed for FLT3+ BP-CML patients to restore BCR::ABL1 TKI sensitivity and prevent BP progression. This evidence concerns the gene ABL1 and acute myeloid leukemia.